Of 516 lung adenocarcinoma (LUAD) cases, 18 (3.5%) had MET and 9 (1.7%) FAM3C CN amplification, 8 deriving from the MET amplification group (Fig. 1d). This evidence concerns the gene FAM3C and lung adenocarcinoma.